Krystal Biotech (KRYS) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Bio-Techne (TECH) over the past year, gaining 77.3% versus a gain of 22.5%. Over five years, KRYS leads with a +566.2% price change compared with -41.7% for TECH. Bio-Techne is the larger company by market cap ($11.37 billion vs $9.67 billion), about 1.2 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs -0.4%).
On valuation, Bio-Techne trades at a lower forward P/E (31.4x vs 35.0x for Krystal Biotech). Bio-Techne pays a dividend yielding 0.44%, while Krystal Biotech does not currently pay one. Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 15.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | TECH |
|---|---|---|
| Share price | $326.60 | $72.52 |
| Market cap | $9.67B | $11.37B |
| 1-day change | +0.63% | -0.02% |
| YTD return | +31.65% | +23.33% |
| 1-year return | +77.34% | +22.54% |
| 5-year return | +566.19% | -41.75% |
| P/E ratio (TTM) | 40.93 | 62.51 |
| Forward P/E | 35.04 | 31.36 |
| EPS (TTM) | $7.98 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $389.13M | $1.22B |
| Revenue growth (YoY) | +33.94% | -0.38% |
| Net income (latest FY) | $204.83M | $181.86M |
| Gross margin | — | 65.77% |
| Operating margin | 41.45% | 20.73% |
| Net margin | 52.64% | 14.97% |
| 52-week high | $382.54 | $72.69 |
| 52-week low | $179.19 | $43.20 |
| Distance from 52-week high | -14.62% | -0.24% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +20.06% | -2.78% |
| Average volume | 380.77K | 3.08M |
| Shares outstanding | 29.60M | 156.82M |
| Employees | 295 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed TECH by 54.8 percentage points over the past year.
- Bio-Techne trades at a higher earnings multiple (62.5x vs 40.9x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 15.0 cents for Bio-Techne.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs -0.38%).
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
KRYS vs TECH FAQ
Which is bigger, Krystal Biotech or Bio-Techne?
Bio-Techne (TECH) is larger, with a market capitalization of $11.37B compared with $9.67B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, KRYS or TECH?
KRYS returned +77.34% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KRYS or TECH?
KRYS has the lower trailing P/E at 40.9, versus 62.5 for TECH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Krystal Biotech or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Krystal Biotech does not currently pay a regular dividend.
Are Krystal Biotech and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.